Radiotherapy in Primary Mediastinal Lymphoma

Instituto Mexicano del Seguro Social198 enrolled

Overview

The use of Rituximab has been proposed to be useful and avoid the use of radiotherapy in diffuse large B-cell lymphoma with bulky disease.We assess efficacy of adjuvant radiotherapy in patients treated with R-CHOP

Study Type

OBSERVATIONAL

Enrollment

198

Conditions

Adjuvant Radiotherapy on Complete Remission Patients

Interventions

no drugsRADIATION

Adjuvant radiotherapy 3.5 G will be administered or not (control group) in patients with mediastinal lymphoma,treated with R-CHOP

Eligibility

Sex: ALLMin age: 18 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: Diagnosis of primary mediastinal lymphoma No previous treatment performance status \< 2 HIV, Hepatis B and C negative Normal :Renal, hepatic, pulmonary and cardiac function Exclusion Criteria: pregnancy \-

Locations (1)

Oncology Research Unit

Mèxico DF, Mexico City, Mexico

Outcomes

Primary Outcomes

measurement of progression free-survival and overall survival at > 5 years

Assess if the use of adjuvant radiotherapy improve outcome in patients with primary mediastinal lymphoma treated initially with R-CHOP

Time frame: 5 years

Secondary Outcomes

assess toxicity secondary to mediastinal radiotherapy

Assess if the addition of mediastinal radiotherapy to patients who received anthracyclines can produce an increase in cardiac toxicity

Time frame: > 5 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.